Research reveals IGFBP6’s role in suppressing vascular inflammation and atherosclerosis, suggesting it as a novel target for cardiovascular disease therapy.
Verve raises $148M via public stock offering, private placement with Eli Lilly (corrected)
After releasing the first-ever results of an in vivo base editing therapy in humans, Verve Therapeutics has priced a public offering of 12.5 million shares
November 30, 2023